Highest-materiality recent filing
cbdMD extends warehouse lease through 2031, cuts footprint and annual rent by ~$450k
Third Amendment to Lease extends term 62 months to Nov 30, 2031 for 40,000 sq ft (down from 80,000).
cbdMD grants RSUs to directors and sets annual cash retainers
Each independent director and non-management employee director receives 1,572 RSUs vesting quarterly through March 31, 2027.
Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
cbdMD buys Bluebird Botanicals CBD e-commerce assets for 425k shares plus 525k earnout
Acquired substantially all assets of Gaia Botanicals d/b/a Bluebird Botanicals: brand, domain, trademarks, inventory.
cbdMD regains NYSE American compliance; BC indicator removed Dec 8, 2025
Received NYSE American letter Dec 5, 2025 confirming compliance with Sections 1003(a)(i) and (ii).
CEO/CFO T. Ronan Kennedy signs 3-year term; base salary of $340,000 per year.
cbdMD Q4 net sales up 3-5% YoY; FY net loss improves to ~$2M from $3.7M
Net sales for fiscal 2025 expected $19.1–19.3M vs $19.5M prior year.
cbdMD raises $1.7M gross via Series B Convertible Preferred, net $1.5M for working capital
Issued 1,700,000 shares of Series B Convertible Preferred to four institutional investors for $1.7M gross proceeds.
cbdMD board grants RSUs to directors, sets annual cash retainers
Each independent director and non-management employee director receives 1,572 RSUs.
cbdMD converts all Series A Preferred to common, effects 1-for-8 reverse stock split
All 5,000,000 outstanding 8% Series A Preferred shares automatically converted into 65,000,000 common shares on May 6, 2025.
cbdMD shareholders approve automatic conversion of Series A Preferred Stock into common at 13:1
Shareholders approved automatic conversion of each Series A Preferred share into 13 common shares, eliminating $6.7M in accrued dividends and $4M annual dividend obligations.
cbdMD fully converts remaining $56K senior secured notes to equity, now debt-free
Remaining $56,000 Senior Secured Convertible Notes converted to common stock on Jan 14, 2025.
cbdMD reduces convertible note debt to $56K; issued 609K shares; Q1 cash ~$2.1M
Convertible note principal reduced to ~$56,000 as holders converted ~$309,000 principal plus accrued interest.
cbdMD receives additional NYSE American noncompliance notice for equity under $2M
Stockholders' equity $1,963,417 as of Sep 30, 2024, below $2M threshold; losses in 4 of 5 recent fiscal years.
cbdMD appoints CEO/CFO Ronan Kennedy to Board, expanding to 5 members
Expanded Board from 4 to 5; Kennedy appointed effective Dec 18/19, 2024.
cbdMD extends warehouse lease through Sep 2026, discloses share issuance on debt conversion
Lease amended: 19-month extension from Mar 1, 2025 to Sep 30, 2026; monthly base rent $65K first year, $67.6K second year.
cbdMD gets NYSE American plan acceptance for listing; equity at $3.1M, deadline Dec 2025
NYSE American accepted cbdMD's plan to regain compliance; plan period through Dec 5, 2025.
cbdMD acquires 'CBD MD' trademark from Majik Medicine for cash/stock; settles litigation
Paid $100k cash on closing; will pay $50k annually for 4 years ($300k total) and issued 75k shares of common stock (50k more in year 2).
cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline
Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.
cbdMD settles former office lease, expects ~$780K in total gains
Paid $255K to satisfy all past due obligations under former lease; mutual release executed.
cbdMD settles former lease with $255K payment, records $550K gain
Made $255,000 payment on Aug 15, 2024 to satisfy all past due lease amounts; mutual release executed.
cbdMD reports 3,763,433 shares outstanding after note conversions; $1.08M notes balance
As of July 19, 2024, common shares outstanding: 3,763,433 after reconciling partial conversions of 8% Senior Secured Convertible Promissory Notes.
cbdMD submits NYSE American compliance plan; expects response in August 2024
Received NYSE American non-compliance notice on June 5, 2024 for continued listing standards.
Stockholders' equity was $3.1M as of March 31, 2024, below $4M minimum required by Section 1003(a)(ii).
Bradley Whitford appointed Chief Accounting Officer, Treasurer, Secretary; annual base salary $200,000.
cbdMD enters forbearance on sublease default, moves executive offices
Behind on rent since Sep 2023; default notice and summary ejectment filed Feb 2024.
cbdMD posts updated investor deck for non-deal roadshows; no material new info
Executives to use new investor presentation in non-deal roadshows starting Feb 29, 2024.
Effective March 29, 2024, the Board of Directors (the "Board") of cbdMD, Inc. (the "Company") appointed Bradley Whitford, the Company's current Vice President of Finance, to serve as the Company's Chief Accounting Officer at the discretion of the Board.
Max materiality 0.85 · Median 0.60 · Most common event other_material